natgillin/translations-raw huggingface dataset:
each Rf is independently hydrogen, fluoro, C1-4 aliphatic, or C1-4 fluoroaliphatic, provided that if X is -0- or -NH-, then Rf is not fluoro; or two Rf taken together form =O; or two R, taken together with the carbon atom to which they are attached, form a 3- to 6-membered carbocyclic ring; or one Rf, taken together with Re and the intervening carbon atoms, forms a 3- to 6-membered spirocyclic ring; Rm is hydrogen, fluoro, -N(R4)2, or an optionally substituted C1-4, aliphatic group; and Rn is hydrogen, fluoro, or an optionally substituted C1-4 aliphatic group; or 
svaki -R9p je nezavisno -C(O)R5, -C(O)N(R4)2, -CO2R6, -SO2R6, -SO2N(R4)2, ili C1-4 alifatična grupa opcijski supstituirana sa R7; svaki Rp nezavisno odabran je iz grupe koja sadrži halo, C1-6 alifatičnu grupu, C1-6 fluoroalifatičnu grupu, -R1p, -R2p, -T2-R1p, i -T2-R2p; ili dva RP na istom zasićenom atomu ugljika, zajedno sa ugljikovim atomom za koji su spojeni, formiraju opcijski supstituirani 3- do 6-člani spirociklični cikloalifatični prsten; je C1-6 alkilen lanac opcijski supstituiran sa R3a ili R3b;
The system of claim 1, wherein the vapor generating inductive heater (805) comprises a ceramic cylinder (850) with a bore (852) therein that is packed with the hypotubes (855). 
Sustav prema zahtjevu 1, naznačen time da induktivni grijač za stvaranje pare (805) sadrži keramički cilindar (850) s otvorom (852) u koji su zapakirane hipocijevi (855).
Preferably in this process, before the step of passing a hollow needle through the closure the area of the closure through which the needle is to pass, preferably the entire outer surface of the closure, more preferably also the entire outer surface of the vial, is sterilised by exposure to radiation. 
Poželjno je da se u tom postupku, prije koraka prolaza šuplje igle kroz zatvarač, prostor zatvarača kroz koji treba proći igla, poželjno cijela vanjska površina zatvarača, još poželjnije također i cijela vanjska površina bočice, sterilizira izlaganjem zračenju.
The method of claim 6 wherein the primary drive signal and the secondary drive signal overlap. 
Sustav prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je sustav namješten tako da se primarni pokretački signal i sekundarni pokretački signal preklapaju.
The IL-17 binding antibody or active fragment thereof according to claim 2, wherein said VH comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1, said CDR2 having the amino acid sequence SEQ ID NO:2, and said CDR3 having the amino acid sequence SEQ ID NO:3 or direct CDR equivalents thereof. 
VH koji obuhvaća u nizu hipervarijabilna područja CDR1-x, CDR2-x i CDR3-x, gdje navedeno područje CDR1-x ima aminokiselinsku sekvencu SEQ ID NO:11, navedeno područje CDR2-x ima aminokiselinsku sekvencu SEQ ID NO:12, i navedeno područje CDR3-x ima aminokiselinsku sekvencu SEQ ID NO:13, dok su hipervarijabilna područja određena prema Chothia-definiciji; i
mixing the binder of step b) with the aqueous mineral pigment material suspension of step a) and adjusting the solids content of the obtained suspension so that it is from 45 to 80 wt.-%, based on the total weight of the suspension; grinding the aqueous mineral material suspension of step c), wherein in step c) the binder is added to the aqueous mineral pigment suspension in an amount from 0.1 to 10.0 wt.-%, based on the total weight of the suspension. 
C) miješanje veziva iz koraka b) s vodenom suspenzijom mineralnog pigmentnog materijala iz koraka a) te podešavanje sadržaja krutina dobivene suspenzije tako da bude od 45 do 80% tež., u odnosu na ukupnu težinu suspenzije; d) usitnjavanje vodene suspenzije mineralnog materijala 12 koraka c), gdje se u koraku c) vezivo dodaje vodenoj suspenziji mineralnog pigmentnog u količini od 0.1 do 10.0% tež., u odnosu na ukupnu težinu suspenzije.
The compound according to claim 1, wherein the substituents of the pair (R1, R5) are identical and the substituents of the pair (R2, R4) are identical. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da su supstituenti para (R1, R5) te supstituenti para (R2, R4) istovjetni.
The use according to any of the preceding claims, wherein the VLP crosses the physiologically intact blood-brain barrier. 
VLP za uporabu u skladu s najmanje jednim od gore navedenih zahtjeva, dok VLP koji sadrži lijek prolazi fiziološki intaktnu barijeru krvi-mozak.
The ingredients of part b were mixed in a second beaker and heated to about 175 degrees Celsius. 
Sastojci dijela b se pomiješaju u drugoj čaši i zagrijavaju do oko 175 stupnjeva Celziusa.
The process for preparing a vaccine composition as claimed in claim 14, wherein the conjugate obtained in b) is combined with diphtheria toxoid, tetanus toxoid, and acellular Bordetella pertussis antigens toxoid, pertactin and filamentous hemagglutinin. 
Postupak za pripravu pripravka cjepiva prema zahtjevu 12 ili 13, naznačen time da se konjugat dobiven u koraku b) kombinira s toksoidom difterije, toksoidom tetanusa, 1 3 acelulama antigena Bordetella pertussis, koji su toksoid, pertaktin 1 filamentozni hemaglutinin.
a variable light chain comprising the CDRs 1, 2 and 3 of the amino acid sequence of SEQ ID NO: 1 and the CDRs 1, 2 and 3 of the amino acid sequence of SEQ ID NO: 3, and a variable heavy chain comprising the CDRs 1, 2 and 3 of the amino acid sequence of SEQ 1D NO: 2 and the CDRs 1, 2 and 3 of the amino acid sequence SEQ ID NO: 5. The bispecific antibody or antibody fragment thereof according to claim 1 that further comprises constant region domains, wherein the constant region domains preferably consist of CH1, CH2, CH3 and CL. The Bispecific antibody or antibody fragment thereof according to one of the claims I or 2, wherein the antibody or antibody fragment thereof neutralizes IL-4 and/or IL-13 activity and preferably neutralizes IL-4 or IL-13 mediated cell proliferation in TF-1 cells. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 i IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLhB-B13-poveznica-VLhBD4-8-CL-C i dva teška lanca sa strukturom N-VHhB-B13-poveznica-VHhBD4-8-CH1-CH2-CH3-C, pri čemu VLhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLhBD4-8 sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHhB-B13 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHhBD4-8 sadrži sekvencu aminokiseline SEQ ID NO: 4, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
Intermediate 31 was prepared (69% yield) according to the procedure for intermediate 26. 
Intermedijer 31 Intermedijer 31 je pripremljen (69% prinos) prema postupku za Intermedijer 26.
Moreover, further problems of the prior art are overcome. 
Dodatno, daljnji problemi iz stanja tehnike su nadvladani.
An herbicidal composition according to claim 7, wherein the saturated or unsaturated fatty acid is oleic acid. 
Herbicidni pripravak prema zahtjevu 7, naznačen time da zasićena ili nezasićena masna kiselina je oleinska kiselina.
said monoclonal antibody is in an amount of 60 mg/mL, said histidine acetate is in a concentration of 20 mM, said sucrose is in a concentration of 120 mM, and said polysorbate is polysorbate 20 in a concentration of 0.04% (w/v), and said formulation has a pH of 5.8; or said monoclonal antibody is in an amount of 125 mg/mL, said histidine acetate is in a concentration of 20 mM, said sucrose is in a concentration of 240 mM, and said polysorbate is polysorbate 20 in a concentration of 0.02%, and said formulation has a pH of 5.5. 
navedeno monoklonsko protutijelo je u količini od 60 mg/ml, navedeni histidin acetat je u koncentraciji od 20 mM, navedena saharoza je u koncentraciji od 120 mM, i navedeni polisorbat je polisorbat 20 u koncentraciji od 0,04 % (m/v), dok navedena formulacija ima pH vrijednost od 5,8; ili navedeno monoklonsko protutijelo je u količini od 125 mg/ml, navedeni histidin acetat je u koncentraciji od 20 mM, navedena saharoza je u koncentraciji od 240 mM, i navedeni polisorbat je polisorbat 20 u koncentraciji od 0,02 %, a navedena formulacija ima pH vrijednost od 5,5.
Use of at least one ground natural calcium carbonate having a d50 (Mal) of between 0.05 and 0.3 µm, in a coating composition comprising at least one pigment having a refractive index of greater than or equal to 2.5, characterised in that for a coating composition having a constant PVC in the range of from 5% up to the CPVC, the gloss and/or opacity of the composition is equal to or greater than the gloss and/or opacity of the same composition implementing said pigment having a refractive index of greater than or equal to 2.5 in place of said ground natural calcium carbonate having a d50 of between 0.05 and 0.3 µm 
Uporaba najmanje jednog usitnjenog prirodnog kalcijevog karbonata koji ima d50 (Mal) između 0.05 i 0.3 um, u sastavu za oblaganje koji obuhvaća barem jedan pigment indeksa refrakcije većeg od ili jednakog 2.5, sastava je jednaka ili veća od sjaja i/ili neprozirnosti istog sastava uvođenjem navedenog pigmenta indeksa refrakcije većeg od ili jednakog 2.5 na mjesto navedenog usitnjenog kalcijevog karbonata koji ima d50 između 0.05 10.3 um.
with piperidine-4-one derivatives, using a suitable reducing agent and base in presence of suitable solvent at ambient temperature to obtain a compound of formula (I), wherein all substitutions are as defined in claim 1 . 
(ID sa derivatima piperidin-4-ona, uz korištenje pogodnog sredstva za redukciju i baze u prisutnosti pogodnog otapala kod temperature okoline da se dobije spoj sa formulom (I), pri čemu su sve supstitucije kako je definirano u zahtjevu 1.
The two elements already exist as individual filaments before the winding process and have to be manufactured in individual separate preliminary processes and are brought together by the winding process. 
Ova dva elementa već postoje kao individualna vlakna prije postupka obavijanja i trebaju se proizvoditi u pojedinačnim odvojenim prethodnim postupcima.
The organic layer is separated, washed with water (2×100 ml), saturated sodium hydrogen carbonate solution (100 ml) and concentrated in vacuo to afford the titled compound as a pale yellow solid which is used crude in the next step. 
Organski sloj se odvoji, ispere s vodom (2 x 100 ml), sa zasićenom otopinom natrijevog hidrogen karbonata (100 ml) i koncentrira se u vakuumu, čime se dobije naslovni spoj kao blijeda žuta kruta tvar koju se koristi sirovu u slijedećem stupnju.
Process for preparing the compound of the formula (II) according to claim 3, comprising reacting the compound of the formula (I) in a solvent with aqueous sodium hydroxide solution with the addition of triethylamine. 
Postupak za pripravu spoja formule (II) prema zahtjevu 3, naznačen time da spoj s formulom (1) reagira u otapalu s vodenom otopinom natrijevog hidroksida uz dodatak trietilamina.
This in turn applies the impulse to the tool string below the jar, thereby tending to free any stuck tooling. 
Na ovaj se način primjenjuje impuls na alat ispod udaraca, težeći pritom da se oslobodi bilo koji zaglavljeni dio alata.
The anti-CD20 antibody formulation for use according to claim 1, wherein the sodium acetate is present in an amount of 50mM. 
Formulacija protutijela an4-CID20 za uporabu prema zahtjevu 1, naznačena time, da je natrijev acetat prisutan u količini od 50 mM.
A composition for use according to claim 1, where the dosing is on a 6 hourly basis. 
Sastav za korištenje prema zahtjevu 1, gdje je doziranje na bazi svakih 6 sati.
An immunoconjugate according to claim 22, wherein said growth inhibitory agent is a cytotoxic agent or a radioactive isotope. 
Imunokonjugat prema patentnom zahtjevu 7, naznačen time što je navedeno sredstvo za inhibiciju rasta citotoksično sredstvo ili radioaktivni izotop.
X-ray powder diffraction confirms pure MTC pentahydrate form A in the residue. A process for the preparation of substantially pure methylthioninium chloride pentahydrate form A, wherein methylthioninium chloride is suspended in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, the suspension is kept at low temperature, and the solid is isolated and dried to remove the organic solvent and any excess water from the solid; 
Postupak proizvodnje bitno čistog metiltioninijklorid pentahidrata u Obliku A, naznačen time, da: a) o metiltioninijklorid se suspendira u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25*C, a pritom se suspenzija drži na niskoj temperaturi, dok se krutina izolira i suši kako bi se odstranilo organsko otapalo i bilo koji višak vode iz krutine; b) metiltioninijklorid se otapa na povišenim temperaturama u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25C, a pritom se otopina hladi, dok se nataložena krutina izolira i suši kako bi se odstranilo organsko otapalo i bilo koji višak vode iz krutine; ili
is hydrogen or a radical of formula 
R* je vodik ili radikal formule t>&
Preferably the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer a single dose. 
Poželjno se pripravak nalazi u obliku za pojedinačno doziranje, na primjer, u obliku tablete, kapsule ili odmjerene doze za isporuku aerosolom, tako da bolesnik može davati pojedinačnu dozu.
= H and X2 = A; and said light chain comprises the O12/IgVk1-39 light chain variable region of figure 23A with 0-5 amino acid substitutions. 
Xi=HiX=G; Xi=DiX=G;ili Xi=HiX= A; navedeni laki lanac sadrži varijabilnu regiju lakog lanca O12/IgVx 1-39 iz slike 23A s 0-5 aminokiselinskih supstitucija.
a heavy chain variable region CDR1 amino acid sequence selected from the group consisting of SEQ ID NOs: 2-7; and 
varijabilno područje jakog lanca CDR1 aminokiselinske sekvence odabrane iz skupine koju čine od SEQ ID NO:2 do SEQ ID NO:7; i
The device as claimed in claim 1, characterized in that it comprises fastening means (16) for fastening four elements (3, 4) together, said elements being placed in a first pair of consecutive elements placed adjacent to a second pair of consecutive elements. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sadrži sredstvo za pričvršćivanje (16), namijenjeno međusobnom pričvršćivanju četiri elementa (3, 4), gdje su navedeni elementi postavljeni u prvom paru uzastopnih elemenata postavljenih uz drugi par uzastopnih elemenata.
Closing mechanism (1) for refrigerated display cabinets (2), according to claim 2, characterised in that the independent frontal displacement means are supported by the body (4) of the display cabinet (2). 
Rashladna vitrina s mehanizmom za zatvaranje (1) u skladu s patentnim zahtjevom 2, naznačena time što tijelo (4) vitrine (2) nosi element za čeono pomicanje pomičnog odjeljka za zatvaranje (3).
providing irbesartan hydrochloride having a maximum particle diameter of not more than 2000 µm, (ii') mixing the irbesartan hydrochloride and one or more excipient(s) to give compression mixture, wherein hydrochlorothiazide is added as a further active ingredient and 
pribavljanje irbesartan hidroklorida čiji najveći promjer čestice nije veći od 2000 um, (ii') miješanje irbesartan hidroklorida i jedne ili više pomoćnih tvari da bi se dobila smjesa za komprimiranje, te
converting Compound 26 to Compound 27: 
(b) prevođenju Spoja 26 u Spoj 27:
converting a compound of formula (Ia-5) into a compound of formula (Ia-7), by reaction with Sn(CH3)4 in the presence of a suitable catalyst and a suitable solvent, wherein R2 to R7, p, q and X are defined as in claim 1; 
(la-6) pri čemu su R* do R', p, qi X kako je definirano u patentnom zahtjevu 1; g) pretvorbu spoja formule (Ia-5) u Spoj formule (Ia-7), reakcijom sa Sn(CH+3)y u prisutnosti pogodnog katalizatora i pogodnog otapala, hal
A heterodimeric antibody comprising two heavy chains with CH3 domains, wherein the CH3 domain of the first heavy chain comprises at least one substitution of a neutral amino acid residue by a positively charged amino acid residue as compared to wildtype, and the CH3 domain of the second heavy chain comprises at least one substitution of a neutral amino acid residue by a negatively charged amino acid residue as compared to wildtype, and wherein the at least one positively charged amino acid residue substituted in the CH3 domain of said first heavy chain interacts with the at least one negatively charged amino acid residue substituted in the CH3 domain of said second heavy chain in the interface between said first and second heavy chains. The heterodimeric antibody of claim 1, wherein the at least one positively charged amino acid residue substitution in the CH3 domain of the first heavy chain is lysine (K). 
Rekombinantna stanica domaćin koja sadrži sekvence nukleinskih kiselina koje kodiraju najmanje dva različita antitijela, naznačena time što svako od navedena dva antitijela sadrži dvije CH3 domene koje su sposobne da formiraju sučelje, pri čemu navedene sekvence nukleinskih kiselina kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizin (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije. Farmaceutski spoj koji sadrži najmanje dva različita antitijela u skladu s patentnim zahtjevom 13 i farmaceutski prihvatljiv nosač. HR P20191446 T1
The suspension system according to claim 1, wherein the floating support securing elements are designed as framework elements of a frame structure or as plates of a frame structure and are arranged for absorbing shearing forces. The suspension system according to claim 1, wherein each of the fixed support securing elements engages a first end of the inner container. 
Spremnički sklop (20, 21, 21′, 22, 22′, 23, 24, 25, 26, 27) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su slobodni nosivi osiguravajući elementi dizajnirani kao rešetkasti elementi okvirne konstrukcije ili kao ploče ili kao ploče okvirne konstrukcije i po mogućnosti služe za apsorbiranje sila smicanja.
A propulsion and steering arrangement according to any one of the preceding claims, wherein the at least one twist angle (a, B) decreases in aft direction to 0° within a range defined by the respective leading edge (12, 13) and the pivot axis (P) of the rudder (10; 10'). 
Raspored pogona i upravljanja prema bilo kojem od prethodnih zahtjeva, pri čemu se barem jedan torzijski kut (a, P) smanjuje u smjeru krme do 0? unutar raspona definiranog odgovarajućim vodećim rubom (12, 13) i središnjom osi (P) kormila (10; 109.
In the illustrated example, said pair of suction cups 3, 4 defines first grip means of the device 1 . 
U prikazanom primjeru navedeni par usisnih čašica 3, 4 određuje prvo sredstvo za zahvaćanje uređaja 1.
removal of the pivaloyl group in position 3 of compound 4 with potassium hydroxide in a tetrahydrofuran/methanol mixture in the presence of sodium perchlorate at room temperature, followed by addition of sulfuric acid to pH 7, whereby 3B,5-dihydroxy-15B,16B-methylen-5B-androst-6-en-17-one 5 is obtained: 
uklanjanje pivaloilne skupine u položaju 3 spoja 4 s kalijevim hidroksidom u smjesi tetrahidrofuran/metanola u prisutnosti natrijevog perklorata pri sobnoj temperaturi, nakon čega slijedi dodatak sumporne kiseline do pH 7, čime se dobiva 3B,5-dihidroksi-15B,16B-metilen-5B-androst-6-en-17-on 5:
(S)-9 or salts thereof. 
(S)-9 ili njegove soli.
any one of the Fc domains of SEQ ID NOs: 23, 24, 25, and 26 in which an amino acid(s) forming the Fc domain is mutated, wherein the Fc domain mutant has reduced FcY receptor-binding activity by said mutation as compared with control polypeptide complex comprising the Fc domain of the same isotype selected from SEQ ID NOs: 23, 24, 25, and 26, and wherein the Fc domain mutant has reduced binding activity to FcYRI, FcYRIIA, FcYRIIB, FcYRIIIA, and/or FcYRIIIB; and a CD3-binding domain, wherein the antigen-binding domain and CD3-binding domain are each a monovalent Fab, and wherein 
(2) bilo koju od Fc domena sa SEQ ID NO: 23, 24, 25, te 26, u kojima je jedna ili više aminokiselina koje tvore Fc domenu mutirana, gdje mutirana Fc domena ima smanjenu aktivnost vezanja na Fcy receptor od strane navedene mutacije u usporedbi s kontrolnim polipeptidnim kompleksom koji sadrži Fc domenu istog izotipa, kojeg se bira između SEQ ID NO: 23, 24, 25, te 26, te gdje mutirana Fc domena ima smanjenu aktivnost vezanja na FcyRI, FcyRIIA, FcyRIIB, FeyRIIIA i/ili FcyRIIIB; i (3) domenu za vezanje na CD3, gdje je svaka od domene za vezanje na antigen i domene za vezanje na CD3 jednovalentni Fab, te gdje:
The method according to claim 7, wherein the condition is HBV infection. 
Molekula za upotrebu u skladu s patentnim zahtjevom 7, naznačena time, da je navedeno stanje HBYV infekcija.
C3-C8 cycloalkyl, optionally substituted with a carboxy or a linear or branched C1-C4 alkoxycarbonyl group, phenyl-linear or branched C1-C6 alkyl,'said C1-C6 alkyl optionally containing one oxygen atom, a heterocyclic or heterocycloalkyl group selected from the group consisting of: 1,3-dioxolane, 2,2-dimethyl-1,3-dioxolane, thiophene, 1-methyl-1-morpholino-4-ylethyl, pyrimidine, pyridine, said pyridine optionally substituted with a hydroxy or C1-C6 alkoxy group; pyridinyl-linear or branched C1-C4 alkyl; piperidine, said piperidine optionally substituted with phenyl-C1-C4 alkyl; furane, tetrahydrofurane; 2-tetrahydrofuran-2-ylethyl, pyrrolidine N-carboxylic acid, C1-C4 linear or branched N-alkoxycarbonylpyrrolidin-2-yl; tetrahydopyrane; or 
-C8 cikloalkila, proizvoljno supstituiranog sa karboksi ili ravne ili razgranate C1-C4 alkoksikarbonil skupine, fenilnog-ravnog ili razgranatog C1-C6 alkila, navedeni C1-C6 alkil proizvoljno sadrži jedan atom kisika, heterocikličke ili heterocikloalkilne skupine odabranih iz skupine koju čine: 1,3-dioksolan, 2,2-dimetil-1,3-dioksolan, tiofen, 1-metil-1-morfolino-4-iletil, pirimidin, piridin, navedeni piridin proizvoljno je supstituiran sa hidroksi ili C1-C6 alkoksi skupinom; piridinil-ravni ili razgranati C1-C4 alkil; piperidin, navedeni piperidin proizvoljno je supstituiran sa fenil-C1-C4 alkilom; furan, tetrahidrofuran; 2-tetrahidrofuran-2-iletil, pirolidin N-karboksilna kiselina, C1-C4 ravni ili razgranati N- alkoksikarbonilpirolidin-2-il; tetrahidopiran; ili
In particular, the formulations according to the present invention are capable of releasing the active ingredient solely in the colon, thus ensuring localized and restricted anti-infectious efficacy. 
Posebno, pripravci prema ovom izumu omogućuju otpuštanje aktivnog sastojka samo u kolonu čime je osigurana lokaliziran i ograničen antiinfektivan učinak.